Vor Bio hires former Sarepta exec to lead commercial strategy; Mallinckrodt poaches CFO from Incyte
→ Vor Bio made a Lazarus-like comeback in late June, nabbing the rights to RemeGen’s autoimmune drug telitacicept after
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
